Mar 13, 2024Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System
Apr 01, 2019Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System
Aug 02, 2017Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity
Oct 07, 2021Spotlight on Innate Immune Science: cGAS-STING’s Role in Human SLE; Cryo-EM Structures of Full-length NLRP3; cGAS- and cGAMP-independent Mode of STING Activation in Niemann–Pick disease type C
Apr 14, 2021Spotlight on Innate Immune Science, MDA5 Edition: New Papers Identify Key Steps in the Activation Mechanism of MDA5
Dec 17, 2020Spotlight on Innate Immune Science, NLRP1 Edition: Both Ends Burning—New Papers Identify Human NLRP1 as a dsRNA Sensor and Provide Structural Insights into NLRP1 Activation by DDP9 Inhibition
